From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 1992
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.83
Pain Relevance 1.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

isomerase activity (Ptgds) transport (Ptgds) Golgi apparatus (Ptgds)
endoplasmic reticulum (Ptgds) lipid metabolic process (Ptgds) cytoplasm (Ptgds)
Anatomy Link Frequency
macrophages 1
fibroblasts 1
melanocytes 1
ARH-77 1
mast cell 1
Ptgds (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 156 98.40 Very High Very High Very High
dexamethasone 3 95.04 Very High Very High Very High
Inflammatory mediators 4 94.48 High High
Inflammatory response 4 85.80 High High
melanocortin 1 receptor 33 81.08 Quite High
Analgesic 1 75.00 Quite High
cytokine 8 44.80 Quite Low
COX-2 inhibitor 20 34.12 Quite Low
cINOD 9 14.80 Low Low
corticosteroid 4 13.92 Low Low
Disease Link Frequency Relevance Heat
Crystal Associated Disease 60 99.62 Very High Very High Very High
INFLAMMATION 167 98.40 Very High Very High Very High
Pressure And Volume Under Development 2 95.68 Very High Very High Very High
Pleurisy 2 93.72 High High
Endometriosis (extended) 1 91.56 High High
Hypersensitivity 9 89.12 High High
Targeted Disruption 3 87.88 High High
Apoptosis 68 87.24 High High
Reprotox - General 1 3 82.64 Quite High
Arthus Reaction 1 79.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Injection of MSU crystals led to a decrease of endogenous PGD2 synthase, whereas intrapouch injection of fibroblasts overexpressing the enzyme resulted in decreased inflammation and expression of pro-inflammatory mediators.
Negative_regulation (decrease) of PGD2 in fibroblasts associated with inflammatory mediators, inflammation and crystal associated disease
1) Confidence 0.55 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206389 Disease Relevance 1.37 Pain Relevance 0.46
raises PGE2, but decreases PGD2, synthesis by zymosan-stimulated murine macrophages [37].
Negative_regulation (decreases) of PGD2 in macrophages
2) Confidence 0.40 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206389 Disease Relevance 0.75 Pain Relevance 0.26
Magnolol was less potent on reducing PGD2 formation in rat mast cell than that of indomethacin.
Negative_regulation (reducing) of PGD2 in mast cell
3) Confidence 0.19 Published 1992 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 1336574 Disease Relevance 0.41 Pain Relevance 0.20
For example, L-type prostaglandin D2 synthase (Ptgds) is expressed at high levels in pigment cells [68] and is repressed in Mc1re/Mc1re skin (current data, [49]); prostaglandin D2 and its derivatives could be one of several mediators released from Mc1r-competent melanocytes that facilitate or potentiate p53 phosphorylation in surrounding cells [69].
Negative_regulation (repressed) of L-type prostaglandin D2 synthase in melanocytes
4) Confidence 0.12 Published 2007 Journal PLoS Genetics Section Body Doc Link PMC1774588 Disease Relevance 0.59 Pain Relevance 0.39
For example, treatment of the COX-2-overexpressing myeloma cell line ARH-77 with indomethacin led to the reduction of PGD2, PGE2, and PGF2?
Negative_regulation (reduction) of PGD2 in ARH-77
5) Confidence 0.07 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2206712 Disease Relevance 0.71 Pain Relevance 0

General Comments

This test has worked.

Personal tools